Quick Answer
Aclaris Therapeutics, Inc. reported Research And Development Expense of $52.65 million for the year ending 2025.
- Aclaris Therapeutics, Inc. showed an increase of +56.7% in Research And Development Expense from 2024 to 2025.
- This data is from Aclaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $1.74 million | Q2 2015: $1.79 million | Q3 2015: $9.41 million | Q1 2016: $9.54 million | Q2 2016: $9.84 million | Q3 2016: $7.16 million | Q1 2017: $7.77 million | Q2 2017: $7.97 million | Q3 2017: $10.86 million | Q1 2018: $13.61 million | Q2 2018: $13.98 million | Q3 2018: $15.19 million | Q1 2019: $19.64 million | Q2 2019: $17.52 million | Q3 2019: $16.18 million | Q1 2020: $7.68 million | Q2 2020: $6.47 million | Q3 2020: $6.24 million | Q1 2021: $7.84 million | Q2 2021: $7.90 million | Q3 2021: $13.98 million | Q1 2022: $14.31 million | Q2 2022: $18.78 million | Q3 2022: $23.66 million | Q1 2023: $22.59 million | Q2 2023: $25.28 million | Q3 2023: $23.88 million | Q1 2024: $9.85 million | Q2 2024: $8.76 million | Q3 2024: $5.96 million | Q1 2025: $11.58 million | Q2 2025: $11.45 million | Q3 2025: $13.03 million.
- Over the full 13 years of available data (2013 to 2025), Aclaris Therapeutics, Inc.'s Research And Development Expense has grown by 1,409.3%.
- Historical annual values: Fiscal year 2025: $52.65 million | Fiscal year 2024: $33.59 million | Fiscal year 2023: $98.38 million | Fiscal year 2022: $77.81 million | Fiscal year 2021: $43.81 million | Fiscal year 2020: $29.34 million | Fiscal year 2019: $64.17 million | Fiscal year 2018: $60.84 million | Fiscal year 2017: $35.80 million | Fiscal year 2016: $33.48 million | Fiscal year 2015: $15.34 million | Fiscal year 2014: $6.51 million | Fiscal year 2013: $3.49 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: